全文获取类型
收费全文 | 108188篇 |
免费 | 46584篇 |
国内免费 | 363篇 |
专业分类
耳鼻咽喉 | 1886篇 |
儿科学 | 5165篇 |
妇产科学 | 1468篇 |
基础医学 | 19820篇 |
口腔科学 | 5621篇 |
临床医学 | 15915篇 |
内科学 | 30209篇 |
皮肤病学 | 8198篇 |
神经病学 | 15502篇 |
特种医学 | 3329篇 |
外科学 | 18453篇 |
综合类 | 1213篇 |
一般理论 | 52篇 |
预防医学 | 6059篇 |
眼科学 | 2844篇 |
药学 | 8112篇 |
中国医学 | 1292篇 |
肿瘤学 | 9997篇 |
出版年
2023年 | 288篇 |
2022年 | 549篇 |
2021年 | 2206篇 |
2020年 | 5567篇 |
2019年 | 11437篇 |
2018年 | 10906篇 |
2017年 | 12038篇 |
2016年 | 12763篇 |
2015年 | 12790篇 |
2014年 | 13018篇 |
2013年 | 13753篇 |
2012年 | 6350篇 |
2011年 | 6407篇 |
2010年 | 10188篇 |
2009年 | 6390篇 |
2008年 | 3882篇 |
2007年 | 2840篇 |
2006年 | 2901篇 |
2005年 | 2608篇 |
2004年 | 2388篇 |
2003年 | 2281篇 |
2002年 | 2194篇 |
2001年 | 1944篇 |
2000年 | 1790篇 |
1999年 | 1201篇 |
1998年 | 391篇 |
1997年 | 290篇 |
1996年 | 276篇 |
1995年 | 222篇 |
1994年 | 214篇 |
1993年 | 203篇 |
1992年 | 503篇 |
1991年 | 467篇 |
1990年 | 451篇 |
1989年 | 411篇 |
1988年 | 359篇 |
1987年 | 386篇 |
1986年 | 341篇 |
1985年 | 289篇 |
1984年 | 218篇 |
1983年 | 159篇 |
1982年 | 104篇 |
1981年 | 96篇 |
1980年 | 97篇 |
1979年 | 146篇 |
1978年 | 96篇 |
1977年 | 81篇 |
1976年 | 86篇 |
1975年 | 84篇 |
1972年 | 78篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
81.
82.
83.
84.
Matrine,oxymatrine, and compound Kushen injection from the roots of Sophora flavescens: an overview of their anticancer activities
下载免费PDF全文
![点击此处可从《中国药学》网站下载免费的PDF全文](/ch/ext_images/free.gif)
In the present review, we updated current information on the chemistry, contents, and anticancer properties of matrine (MT), oxymatrine (OMT), and compound Kushen injection (CKI). The anticancer properties were focused on lung, breast, and liver cancer cells because they are most susceptible. Sources of information were from Google, Google Scholar, PubMed, PubMed Central, Science Direct, PubChem, J-Stage, Directory of Open Access Journals (DOAJ), and China National Knowledge Infrastructure (CNKI). Reference was also made on botanical websites, such as Flora of China and World Flora Online. MT and OMT are dominant quinolizidine alkaloids from the roots of Sophora flavescens (Kushen) of the family Fabaceae. Against lung, breast, and liver cancer cells, MT and OMT inhibit cell proliferation; induce cell cycle arrest, apoptosis, and autophagy; restrict angiogenesis; and inhibit cell metastasis, invasion, and migration. The processes involve various molecular targets and signaling pathways. CKI is a traditional Chinese medicine (TCM) composed of root extracts of S. flavescens and Smilax glabra (Baituling) of the family Smilacaceae. With MT and OMT as major components, CKI has been approved for the treatment of cancer in China more than 20 years ago. In recent years, systematic reviews and meta-analysis have been undertaken to evaluate the anticancer effects of CKI. When CKI is used alone and in combination with chemotherapy of western medicine, there is much to be learned concerning their interactions besides their individual and integrated efficacy. Some perspectives of MT, OMT, and CKI are discussed, and their suggestions for future research are provided. 相似文献
85.
86.
87.
88.
Tuberculosis (TB) remains one of a major health problem worldwide. Tuberculosis vaccine research has made an extraordinary progress over the past few years. However, there is still no replacement for the Bacillus Calmette‐Guérin vaccine, the only TB vaccine licensed for human use. Therefore, the discovery and development of new TB vaccines remains a priority. This article discusses current strategies used to diversify TB vaccines and includes discussion of the status of efforts to improve protection against Mycobacterium tuberculosis (M tb) infection or TB disease by developing new and safe TB vaccines. This article also highlights the current research efforts in immune‐enhancing approaches to improve vaccination efficacy. The development of more effective TB vaccines might have significant impact on global TB control. 相似文献
89.
Erika Cecon Anna Ivanova Marine Luka Florence Gbahou Anne Friederich Jean‐Luc Guillaume Patrick Keller Klaus Knoch Raise Ahmad Philippe Delagrange Michele Solimena Ralf Jockers 《Journal of pineal research》2019,66(2)
Melatonin receptors play important roles in the regulation of circadian and seasonal rhythms, sleep, retinal functions, the immune system, depression, and type 2 diabetes development. Melatonin receptors are approved drug targets for insomnia, non‐24‐hour sleep‐wake disorders, and major depressive disorders. In mammals, two melatonin receptors (MTRs) exist, MT1 and MT2, belonging to the G protein‐coupled receptor (GPCR) superfamily. Similar to most other GPCRs, reliable antibodies recognizing melatonin receptors proved to be difficult to obtain. Here, we describe the development of the first monoclonal antibodies (mABs) for mouse MT1 and MT2. Purified antibodies were extensively characterized for specific reactivity with mouse, rat, and human MT1 and MT2 by Western blot, immunoprecipitation, immunofluorescence, and proximity ligation assay. Several mABs were specific for either mouse MT1 or MT2. None of the mABs cross‐reacted with rat MTRs, and some were able to react with human MTRs. The specificity of the selected mABs was validated by immunofluorescence microscopy in three established locations (retina, suprachiasmatic nuclei, pituitary gland) for MTR expression in mice using MTR‐KO mice as control. MT2 expression was not detected in mouse insulinoma MIN6 cells or pancreatic beta‐cells. Collectively, we report the first monoclonal antibodies recognizing recombinant and native mouse melatonin receptors that will be valuable tools for future studies. 相似文献
90.